MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Anxiety"

  • 2024 International Congress

    Effect of Target Selection on Mood, Pain, and Medications after DBS in PD

    J. Jiao, B. Brumbach, Y. Lin, A. Ko, D. Safarpour (Palo Alto, USA)

    Objective: To describe the association between medication adjustments with mood and pain following bilateral deep brain stimulation (DBS) in Parkinson’s disease (PD). Background: Depression, anxiety,…
  • 2024 International Congress

    Unwinding Anxiety: Feasibility and Effectiveness of App-Based Mindfulness Training for People with Anxiety and Parkinson’s Disease: A Pilot Study

    E. Weisbach, A. Demarco, J. Molino, A. Seritan, P. Prakash (Providence, USA)

    Objective: To assess whether an app-based mindfulness training (MT) intervention, “Unwinding Anxiety”, can be used for Parkinson’s Disease (PD) patients with mild-moderate anxiety to reduce…
  • 2024 International Congress

    Nocturnal Blood Pressure, Non-Dipping, Psychosis And Non-Motor Symptoms In Early Stages Of Huntington’s Disease Patients

    R. Singh, V. Sharma (New Delhi, India)

    Objective: The aim of this study was to determine the relationship between 24 h ambulatory blood pressure measurements (ABPM), i.e., absence or presence of nocturnal…
  • 2023 International Congress

    Angiotensin II Type 1 (AT1) receptor antagonists as potential candidates for anxiety treatment in Parkinson’s Disease

    S. Bordet, L. Grasso, L. Udovin, G. Chevalier, M. Otero-Losada, F. Capani, S. Perez-Lloret (Buenos Aires, Argentina)

    Objective: The aim of this study was to explore the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) on…
  • 2023 International Congress

    Effects of Motor Subtype Stability on Non-Motor Symptoms in Early Parkinson’s Disease

    S. Ng, N. Chia, X. Choi, D. Heng, S. Neo, ZY. Xu, KY. Tay, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

    Objective: To determine the effects of motor subtypes’ stability on non-motor symptoms (NMS) over three years in early Parkinson’s disease (PD). Background: Research have found…
  • 2023 International Congress

    Anxiety in Parkinson’s disease is associated with changes in brain structural connectivity

    G. Carey, R. Viard, R. Lopes, G. Kuchcinski, L. Defebvre, A. Leentjens, K. Dujardin (Lille, France)

    Objective: The aim of this study was to identify White Matter (WM) changes by comparing Parkinson's disease (PD) patients with and without anxiety, using diffusion-tensor…
  • 2023 International Congress

    Genetic and psychiatric risk factors for impulse control disorders in de novo Parkinson’s disease

    M. Ruitenberg, E. Whooley, H. Macdonald, V. Koppelmans (Leiden, Netherlands)

    Objective: To assess the interplay of polygenic dopamine risk scores and psychiatric symptoms in the development of impulse control disorders (ICDs) in de novo patients…
  • 2023 International Congress

    Psilocybin therapy for depression and anxiety associated with Parkinson’s disease: a pilot study (NCT04932434)

    E. Bradley, K. Sakai, G. Fernandes, C. Ludwig, M. Bock, J. Ostrem, C. Tanner, A. O'Donovan, P. Finley, Z. Busby, A. Mckernan, R. Zuzuarregui, A. Penn, A. Wang, A. Theberge, R. Rosen, J. Woolley (San Francisco, USA)

    Objective: To investigate the safety, tolerability, feasibility, and preliminary efficacy of moderate and high dose psilocybin treatment with psychotherapeutic support for comorbid Parkinson's disease (PD)…
  • 2023 International Congress

    The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: findings from the Parkinson’s Progression Markers Initiative

    N. Dahodwala, D. Weintraub, M. Bock, R. Cho, C. Caspell-Garcia, E. Brown, R. Dobkin (Philadelphia, USA)

    Objective: To determine the functional consequences of baseline anxiety symptoms and the longer-term impact of initiation of anxiety treatment in Parkinson’s disease (PD). Background: While…
  • 2023 International Congress

    Healthcare experiences of People with Parkinson’s Disease (PwP) during COVID-19 pandemic

    V. Tomantschger, A. Tautscher-Basnett, C. Hohenwarter (Hermagor, Austria)

    Objective: To investigate how our group of PwP coped with healthcare issues during the pandemic. Background: COVID-19 pandemic led to changes in how healthcare services…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley